Seeking Alpha

Rosetta Genomics Ltd. (ROSG)

  • Jan. 13, 2014, 8:17 AM
    • Rosetta Genomics (ROSG) soars 25% premarket.
    • The company says it has "signed a master service provider agreement with an undisclosed major global biopharmaceutical company."
    • The deal calls for ROSG to "provide its microRNA profiling and other services pursuant to a collaboration in important areas of unmet medical need." (PR)
  • Dec. 9, 2013, 9:15 AM
    • Rosetta Genomics (ROSG) soars 20% premarket as the company says the New York State Department of Health has granted conditional approval for ROSG's kidney cancer test.
    • "With this approval, [we] can offer the Rosetta Kidney Cancer Test in all 50 U.S. states," the company says. (PR)
  • Dec. 9, 2013, 9:15 AM
    | 1 Comment
  • Oct. 30, 2013, 2:16 PM
    • Rosetta Genomics (ROSG -19.1%) slides hard on heavy volume.
    • The move appears to be attributable to Aegis, where analysts have downgraded the shares to Hold from Buy.
    • Price target is now $3.50 (from $10).
    | Comment!
  • Oct. 22, 2013, 10:09 AM
    • Rosetta Genomics (ROSG +2.9%) receives a U.S. patent for a test that differentiates between lung squamous carcinoma and other non small cell lung cancers.
    • From the description: "The invention provides specific nucleic acid sequences for use in the identification, classification and diagnosis of specific lung cancers. The nucleic acid sequences can also be used as prognostic markers for prognostic evaluation of a subject based on their expression pattern in a biological sample." (full text)
    | Comment!
  • Sep. 12, 2013, 9:50 AM
    • The Patent Office grants Rosetta Genomics (ROSG) a Notice of Allowance in connection with the company's screening test for preeclampsia, which affects 3-5% of pregnancies, and is characterized by high blood pressure and large amounts of protein in the urine. The condition can be fatal to mothers and babies.
    • Shares are +14.2%. (PR)
    | Comment!
  • Sep. 12, 2013, 9:11 AM
    | Comment!
  • Sep. 10, 2013, 9:18 AM
    • Rosetta Genomics (ROSG): 1H13 EPS of -$0.64 vs. $3.25 in 1H12.
    • Revenue of $193K vs. 51K in 1H12. Shares +1.5% premarket. (PR)
    | Comment!
  • Jun. 13, 2013, 12:46 PM
    Rosetta Genomics (ROSG +8.3%) pops after Novitas Solutions, the designated Medicare Administrative Contractor for the company's microRNA-based diagnostic assays, rules that ROSG's microRNA assay is reasonable and necessary for providing an important niche in pathologic diagnoses of cancer. The final determination confirms continued Medicare coverage for ROSG's Cancer Origin Test.
    | 1 Comment
  • Jun. 7, 2013, 12:45 PM
    Midday top 10 gainers: OSH +23%. WSBF +19%. OPTT +17%. CSFS +14%. BDBD +13%. JKS +11%. ROSG +11%. THO +10%. ECTY +10%. KFS +9%.
    Midday top 10 Losers: FSGI -56%. TIVO -17%. USM -17%. IRM -16%. ZQK -12%. JRCC -11%. LQDT -11%. AFFY -10%. CBPO -10%. TRUE -8%.
    | Comment!
  • Jun. 7, 2013, 12:23 PM
    Rosetta Genomics (ROSG +11.8%) jumps today after it announcing the execution of a credentialing agreement with Three Rivers Provider Network for the Rosetta Cancer Origin Test. Three Rivers is one of the largest supplemental PPO's in the U.S., providing healthcare benefits to more than 10M members nationwide.
    | Comment!
  • Jun. 7, 2013, 9:16 AM
    Shares of Rosetta Genomics (ROSG) soar 16% premarket after the company signs a credentialing agreement with Three Rivers Provider Network for the Rosetta Cancer Origin Test (miRview). This marks ROSG's second executed agreement with a U.S. PPO in the last three weeks (I, II). (PR)
    | Comment!
  • Jun. 7, 2013, 9:11 AM
    Premarket gainers: ROSG +16%. JKS +15%. IMUC +10%. NLST +8%. CBK +8%. GFA +7%. SNTA +7%. ELN +5%.
    Losers: FSGI -42%. TIVO -18%. IRM -15%. JRCC -14%. LAMR -9%. CPRT -8%. FRO -7%. EQIX -8%. OIS -8%.
    | Comment!
  • Jun. 6, 2013, 9:04 AM
    Rosetta Genomics (ROSG) jumps 10.6% premarket after saying the peer-reviewed journal Molecular Cancer, has accepted a manuscript outlining the ability of the company's miRview test (I, II) to accurately "identify the tumor of origin." In short, the test's predictions agreed with the final diagnosis in 92% of the 84 patients from which samples were taken. (PR)
    | Comment!
  • Jun. 4, 2013, 9:17 AM
    Rosetta Genomics (ROSG), which recently signed its first U.S. PPO agreement, rises 6.5% premarket after saying it is expanding its sales presence in the U.S. to 12 territories from five. The company also says its miRview test "has been trending positively for the past three months in terms of samples processed and samples billed." (PR)
    | Comment!
  • May. 21, 2013, 2:31 PM
    Shares of Rosetta Genomics (ROSG +2.4%) recovered from early losses to trade back near the prior day's highs after the company announced yesterday that it had signed a credentialing agreement with PPO provider Prime Health Services under which ROSG's miRview mets2 test will be included in Prime's covered products and services.
    | Comment!
Visit Seeking Alpha's
ROSG vs. ETF Alternatives
Company Description
Rosetta Genomics Ltd is engaged in the development and commercialization of new diagnostic tests and therapeutics based on a group of genes known as microRNAs.